Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
20.30
-0.12 (-0.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
29
30
31
32
33
34
35
36
Next >
Tough Slogging Ahead for Investors, Diversification is Important
↗
March 07, 2022
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows.
Via
Talk Markets
Where Sarepta Therapeutics Stands With Analysts
↗
March 02, 2022
Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and...
Via
Benzinga
Sarepta Therapeutics: Q4 Earnings Insights
↗
March 01, 2022
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
↗
March 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine...
Via
Benzinga
Earnings Scheduled For March 1, 2022
↗
March 01, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...
Via
Benzinga
Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership
↗
February 01, 2022
Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to
Via
Benzinga
Analyst Ratings For Sarepta Therapeutics
↗
January 18, 2022
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:
Via
Benzinga
Expert Ratings For Sarepta Therapeutics
↗
December 09, 2021
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed th...
Via
Benzinga
Sarepta Therapeutics's Earnings Outlook
↗
February 28, 2022
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
↗
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
↗
January 14, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our...
Via
Benzinga
Analyst Ratings For Sarepta Therapeutics
↗
November 04, 2021
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:...
Via
Benzinga
Expert Ratings For Sarepta Therapeutics
↗
October 15, 2021
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:
Via
Benzinga
Sarepta Abandons Lysogene-Partnered Pivotal-Stage Gene Therapy Candidate
↗
January 13, 2022
Sarepta Therapeutics Inc (NASDAQ: SRPT) is walking away from a three-year licensing pact for a rare disease gene therapy candidate, leaving its former partner on...
Via
Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
↗
January 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
↗
January 05, 2022
UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
↗
November 05, 2021
Upgrades For IGM Biosciences Inc (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
↗
December 09, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:
Via
Benzinga
Why Sarepta Therapeutics Shares Dropped More Than 16% This Week
↗
November 04, 2021
The biotech stock fell a little more than $72 since its close last Friday.
Via
The Motley Fool
Sarepta Therapeutics (SRPT) Q3 2021 Earnings Call Transcript
↗
November 04, 2021
SRPT earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
↗
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Is This Beaten Down Biotech a Bad News Buy?
↗
October 20, 2021
It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?
Via
The Motley Fool
Earnings Scheduled For November 3, 2021
↗
November 03, 2021
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion....
Via
Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
↗
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Why Sarepta Therapeutics Fell 14.7% This Week
↗
October 14, 2021
Investors were unimpressed by the company's clinical and financial news.
Via
The Motley Fool
50 Biggest Movers From Yesterday
↗
October 14, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating...
Via
Benzinga
Why Sarepta Therapeutics Tumbled Today
↗
October 13, 2021
Investors weren't wowed by a company update, or by news of a fresh stock issue.
Via
The Motley Fool
40 Stocks Moving In Wednesday's Mid-Day Session
↗
October 13, 2021
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
October 13, 2021
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7...
Via
Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
↗
October 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...
Via
Benzinga
< Previous
1
2
...
29
30
31
32
33
34
35
36
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
